OPKO Health, Inc. (NASDAQ: OPK) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.2B. The Maz Rating grades it against the other companies in its sector.
OPKO Health, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.62, OPKO Health, Inc. trades at 2.4x sales and 1.1x book value. Over the last twelve months it generated about $500M of revenue and a net loss of $143M. It runs a gross margin of 38.6%, an operating margin of -25.5% and a net margin of -29.5%. It shows return on equity of -12.4%, return on invested capital of -5.8% and a free cash flow yield of -11.3%. On the balance sheet: a debt-to-equity ratio of 0.46 and a current ratio of 4.97. Over the past 52 weeks the share price ranged from $0.98 to $1.86, with a beta of 1.53.
OPKO Health, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 9 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, OPKO Health, Inc. (OPK) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 40.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 36.5% / 30% · Interest income / Revenue 4.41% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 40.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 32.8% / 33% · Receivables / Mkt Cap (36m) 7.34% / 49% · Interest income / Revenue 4.41% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 40.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 32.8% / 33.33% · Receivables / Mkt Cap (24m) 7.34% / 33.33% · Interest income / Revenue 4.41% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 20.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 18.7% / 33.33% · Receivables / Avg Assets (4Q) 5.81% / 33.33% · Interest income / Revenue 4.41% / 5% | Pass |
| FTSE | Debt / Total Assets 25.3% / 33.33% · (Cash+ST Inv) / Total Assets 20.8% / 33.33% · (Cash+Recv) / Total Assets 25.4% / 33.33% · Interest income / Revenue 4.41% / 5% | Pass |
It depends on the standard you follow. As of September 2026, OPKO Health, Inc. (OPK) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. OPKO Health, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 4.41% of each dividend: OPKO Health, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.